Download
Upload.pdf 2,38MB
WeightNameValue
1000 Titel
  • Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report
1000 Autor/in
  1. Pfaar, Oliver |
  2. Bergmann, Karl-Christian |
  3. Bonini, Sergio |
  4. Compalati, Enrico |
  5. Domis, Nathalie |
  6. de BLAY, Frédéric |
  7. de Kam, Pieter-Jan |
  8. Devillier, Philippe |
  9. Durham, Stephen |
  10. Ellis, Anne K. |
  11. Gherasim, Alina |
  12. Haya, Laura |
  13. Hohlfeld, Jens |
  14. Horak, Friedrich |
  15. Iinuma, Tomohisa |
  16. Jacobs, Robert L. |
  17. Jacobi, Henrik Hugo |
  18. Jutel, Marek |
  19. Kaul, Susanne |
  20. Kelly, Suzanne |
  21. Klimek, Ludger |
  22. Larché, Mark |
  23. Lemell, Patrick |
  24. Mahler, Vera |
  25. Nolte, Hendrik |
  26. Okamoto, Yoshitaka |
  27. Patel, Piyush |
  28. Rabin, Ronald |
  29. Rather, Cynthia |
  30. Sager, Angelika |
  31. Salapatek, Anne Marie |
  32. Sigsgaard, Torben |
  33. Togias, Alkis |
  34. Willers, Christoph |
  35. Yang, William H. |
  36. Zieglmayer, René |
  37. Zuberbier, Torsten |
  38. zieglmayer, petra |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-11-28
1000 Erschienen in
1000 Quellenangabe
  • 76(12):3589-3612
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1111/all.14957 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. Although methodologically insulated from the variability of natural pollen exposure, chamber models remain confined to supporting secondary, rather than primary, endpoints in Phase III registration trials. The need for further validation in comparison with field exposure is clearly mandated. On this basis, the European Academy of Allergy and Clinical Immunology (EAACI) initiated a Task Force in 2015 charged to gain a better understanding of how AECs can generate knowledge about respiratory allergies and can contribute to the clinical development of treatments. Researchers working with AECs worldwide were asked to provide technical information in eight sections: (i) dimensions and structure of the AEC, (ii) AEC staff, (iii) airflow, air processing, and operating conditions, (iv) particle dispersal, (v) pollen/particle counting, (vi) safety and non-contamination measures, (vii) procedures for symptom assessments, (viii) tested allergens/substances and validation procedures. On this basis, a minimal set of technical requirements for AECs applied to the field of allergology is proposed.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal allergen exposure chambers
lokal clinical trials
gnd 4001257-8 Allergie
lokal technical standards
lokal allergen immunotherapy
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-4374-9639|https://d-nb.info/gnd/130338249|https://orcid.org/0000-0003-0079-3031|https://frl.publisso.de/adhoc/uri/IENvbXBhbGF0aSwgRW5yaWNvICAgIA==|https://frl.publisso.de/adhoc/uri/ICBEb21pcywgTmF0aGFsaWUgICAgIA==|https://orcid.org/0000-0001-5678-2214|https://orcid.org/0000-0003-0859-4862|https://orcid.org/0000-0001-6054-1886|https://orcid.org/0000-0001-5264-6207|https://frl.publisso.de/adhoc/uri/ICAgRWxsaXMsIEFubmUgSy4gICA=|https://orcid.org/0000-0002-3198-1396|https://orcid.org/0000-0001-7136-1696|https://orcid.org/0000-0003-2646-6186|https://orcid.org/0000-0001-5914-7830|https://orcid.org/0000-0002-9940-5520|https://frl.publisso.de/adhoc/uri/IEphY29icywgUm9iZXJ0IEwuICAgIA==|https://frl.publisso.de/adhoc/uri/IEphY29iaSwgSGVucmlrIEh1Z28gICAg|https://frl.publisso.de/adhoc/uri/IEp1dGVsLCBNYXJlayAgICA=|https://frl.publisso.de/adhoc/uri/IEthdWwsIFN1c2FubmUgICAg|https://orcid.org/0000-0001-7863-3981|https://orcid.org/0000-0002-2455-0192|https://frl.publisso.de/adhoc/uri/ICBMYXJjaMOpLCBNYXJrICAgICA=|https://orcid.org/0000-0003-0262-4047|https://d-nb.info/gnd/1115010409|https://frl.publisso.de/adhoc/uri/ICAgTm9sdGUsIEhlbmRyaWsgICAg|https://orcid.org/0000-0001-9352-1582|https://frl.publisso.de/adhoc/uri/UGF0ZWwsIFBpeXVzaCAgIA==|https://frl.publisso.de/adhoc/uri/UmFiaW4sIFJvbmFsZA==|https://frl.publisso.de/adhoc/uri/IFJhdGhlciwgQ3ludGhpYSAgICA=|https://frl.publisso.de/adhoc/uri/IFNhZ2VyLCBBbmdlbGlrYSAgICAg|https://orcid.org/0000-0002-3224-5673|https://orcid.org/0000-0002-2043-7571|https://orcid.org/0000-0001-9009-5717|https://frl.publisso.de/adhoc/uri/V2lsbGVycywgQ2hyaXN0b3BoICAg|https://frl.publisso.de/adhoc/uri/ICBZYW5nLCBXaWxsaWFtIEguICAgICA=|https://frl.publisso.de/adhoc/uri/WmllZ2xtYXllciwgUmVuw6kgICAgIA==|https://orcid.org/0000-0002-1466-8875|https://orcid.org/0000-0001-5432-9459
1000 Label
1000 Förderer
  1. European Academy of Allergy and Clinical Immunology |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer European Academy of Allergy and Clinical Immunology |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6432117.rdf
1000 Erstellt am 2022-03-10T11:44:00.921+0100
1000 Erstellt von 323
1000 beschreibt frl:6432117
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Thu Mar 31 07:52:23 CEST 2022
1000 Objekt bearb. Thu Mar 31 07:52:07 CEST 2022
1000 Vgl. frl:6432117
1000 Oai Id
  1. oai:frl.publisso.de:frl:6432117 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source